Research statistics
Pemvidutide research: publications and trials
At a glance
Publications, all years
14
Since 2011
Publications in 2026 so far
6
Through November 15, 2026
Human clinical research
35.7%
5 of 14 classified
Registered clinical trials
16
ClinicalTrials.gov
Randomized controlled trials
4
Publications reporting an RCT in people
Systematic reviews and meta-analyses
3
Preclinical studies
14.3%
1 animal · 0 in vitro · 1 computational
Records that only mention it
5
Not counted above
Status in the library: In clinical trials. Groups: GLP-1 receptor agonists.
What to keep in mind
- Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Pemvidutide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2011 | 1 | 0 | 0 | 0 | 1 |
| 2022 | 0 | 1 | 0 | 0 | 1 |
| 2024 | 1 | 0 | 1 | 0 | 2 |
| 2025 | 2 | 0 | 1 | 1 | 4 |
| 2026 (to date) | 1 | 1 | 4 | 0 | 6 |
Study types
| Randomized controlled trial | 4 |
|---|---|
| Review | 3 |
| Meta-analysis | 2 |
| Animal study | 1 |
| Other clinical trial | 1 |
| Computational study | 1 |
| Editorial, letter or other | 1 |
| Systematic review | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Metabolic health | 9 |
|---|---|
| Gastrointestinal | 7 |
| Obesity and weight management | 6 |
| Endocrinology | 4 |
| Cardiovascular | 2 |
| Neurological and mental health | 1 |
| Oncology | 1 |
Registered clinical trials
4 of 8 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 10 · Terminated: 3 · Active, not recruiting: 1 · Recruiting: 1 · Withdrawn: 1
Phase 1: 7 · Phase 1 / Phase 2: 4 · Phase 2: 4 · Phase 3: 1
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.
Digestive diseases (Basel, Switzerland) · November 9, 2026 · Meta-analysis · cited 0 times · open access
PMID 43002386 · DOI 10.1159/ddi/acnag020 · Reviews and meta-analyses
- Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.
Naunyn-Schmiedeberg's archives of pharmacology · March 25, 2026 · Meta-analysis · cited 0 times
PMID 41879841 · DOI 10.1007/s00210-026-05257-1 · Reviews and meta-analyses
- Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.
Addictive behaviors reports · January 30, 2026 · Systematic review · cited 6 times · open access
PMID 41696398 · DOI 10.1016/j.abrep.2026.100671 · Reviews and meta-analyses
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.
The lancet. Gastroenterology & hepatology · November 11, 2026 · Randomized controlled trial · cited 0 times
PMID 43014327 · DOI 10.1016/s2468-1253(26)00263-3 · Human clinical research
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
Lancet (London, England) · November 11, 2025 · Randomized controlled trial · cited 43 times
PMID 41237796 · DOI 10.1016/s0140-6736(25)02114-2 · Human clinical research
- Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.
JHEP reports : innovation in hepatology · June 18, 2025 · Randomized controlled trial · cited 14 times · open access
PMID 41113119 · DOI 10.1016/j.jhepr.2025.101483 · Human clinical research
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
Journal of hepatology · July 11, 2024 · Randomized controlled trial · cited 178 times · open access
PMID 39002641 · DOI 10.1016/j.jhep.2024.07.006 · Human clinical research
- Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research · October 12, 2011 · Other clinical trial · cited 54 times · open access
PMID 21994418 · DOI 10.1158/1078-0432.ccr-11-1817 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
Journal of hepatology · July 11, 2024 · Randomized controlled trial · cited 178 times · open access
PMID 39002641 · DOI 10.1016/j.jhep.2024.07.006 · Human clinical research
- Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research · October 12, 2011 · Other clinical trial · cited 54 times · open access
PMID 21994418 · DOI 10.1158/1078-0432.ccr-11-1817 · Human clinical research
- Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
Scientific reports · April 23, 2022 · Animal study · cited 52 times · open access
PMID 35461369 · DOI 10.1038/s41598-022-10577-2 · Animal studies
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
Lancet (London, England) · November 11, 2025 · Randomized controlled trial · cited 43 times
PMID 41237796 · DOI 10.1016/s0140-6736(25)02114-2 · Human clinical research
- Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.
Indian journal of endocrinology and metabolism · September 4, 2024 · Review · cited 17 times · open access
PMID 39676791 · DOI 10.4103/ijem.ijem_442_23 · Reviews and meta-analyses
Latest publications
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.
The lancet. Gastroenterology & hepatology · November 11, 2026 · Randomized controlled trial · cited 0 times
PMID 43014327 · DOI 10.1016/s2468-1253(26)00263-3 · Human clinical research
- GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.
Digestive diseases (Basel, Switzerland) · November 9, 2026 · Meta-analysis · cited 0 times · open access
PMID 43002386 · DOI 10.1159/ddi/acnag020 · Reviews and meta-analyses
- Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.
Cureus · June 29, 2026 · Review · cited 0 times · open access
PMID 42529769 · DOI 10.7759/cureus.111728 · Reviews and meta-analyses
- Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.
Naunyn-Schmiedeberg's archives of pharmacology · March 25, 2026 · Meta-analysis · cited 0 times
PMID 41879841 · DOI 10.1007/s00210-026-05257-1 · Reviews and meta-analyses
- Systemic Pharmacokinetic Principles of Therapeutic Peptides.
Clinical pharmacokinetics · February 9, 2026 · Computational study · cited 3 times · open access
PMID 41661442 · DOI 10.1007/s40262-025-01615-z · Computational studies
- Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.
Addictive behaviors reports · January 30, 2026 · Systematic review · cited 6 times · open access
PMID 41696398 · DOI 10.1016/j.abrep.2026.100671 · Reviews and meta-analyses
- The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.
Lancet (London, England) · December 1, 2025 · Editorial, letter or other · cited 2 times
PMID 41352959 · DOI 10.1016/s0140-6736(25)02304-9 · Commentary and other
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
Lancet (London, England) · November 11, 2025 · Randomized controlled trial · cited 43 times
PMID 41237796 · DOI 10.1016/s0140-6736(25)02114-2 · Human clinical research
- Review: Special Issue: <i>Real-world evidence on the use of GLP1 receptor agonists</i>: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.
Drugs in context · July 24, 2025 · Review · cited 2 times · open access
PMID 40734920 · DOI 10.7573/dic.2025-4-8 · Reviews and meta-analyses
- Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.
JHEP reports : innovation in hepatology · June 18, 2025 · Randomized controlled trial · cited 14 times · open access
PMID 41113119 · DOI 10.1016/j.jhepr.2025.101483 · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: ALT-801; Pemvidutide
((TITLE_ABS:"ALT-801" OR CHEM:"ALT-801" OR TITLE_ABS:"ALT801" OR CHEM:"ALT801") OR (TITLE_ABS:"Pemvidutide" OR CHEM:"Pemvidutide")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Pemvidutide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/pemvidutide